Page 153 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 153
125. Klotz L, Zhang L, Lam A, et al. A Clinical 135. Porten SP, Whitson JM, Cowan JE, et al.
results of long-term follow-up of a large, Changes in prostate cancer grade on serial
active surveillance cohort with localized biopsy in men undergoing active
prostate cancer. J Clin Oncol 2010;28:126- surveillance. Journal of Clinical Oncology
131. 2011;29:2795-2800.
126. Fryback DG, Albertsen PC, Storer BE. 136. Ng MK, Van AN, Thomas K, et al. Prostate-
Prostatectomy and survival among men with specific antigen (PSA) kinetics in untreated,
clinically localized prostate cancer. JAMA localized prostate cancer: PSA velocity vs
1996;276:1723-1724. PSA doubling time. BJU Int 2009;103:872-
127. Neulander EZ, Duncan RC, Tiguert R, et al. 876.
Deferred treatment of localized prostate 137. Carter HB, Kettermann A, Warlick C, et al.
cancer in the elderly: the impact of the age Expectant management of prostate cancer
and stage at the time of diagnosis on the with curative intent: an update of the Johns
treatment decision. BJU Int 2000;85:699- Hopkins experience. J Urol. 2007;178:2359-
704. 2364.
128. Venkitaraman R, Thomas K, Grace P, et al. 138. Jones GW. Prospective, conservative
Baseline urinary phytoestrogen levels and management of localized prostate cancer.
the natural history of untreated, localised Cancer 1992;70:307-310.
prostate cancer in a British population. Int J 139. Johansson JE. Expectant management of
Biol Markers 2008;23:192-197.
early stage prostatic cancer: Swedish
129. Krakowsky Y, Loblaw A, Klotz L. Prostate experience. J Urol 1994;152:1753-1756.
cancer death of men treated with initial
active surveillance: clinical and biochemical 140. Adolfsson J, Tribukait B, Levitt S. The 20-
Yr outcome in patients with well- or
characteristics. J Urol 2010;184:131-135.
moderately differentiated clinically localized
130. Loblaw A, Zhang L, Lam A, et al. prostate cancer diagnosed in the pre-PSA
Comparing prostate specific antigen triggers era: the prognostic value of tumour ploidy
for intervention in men with stable prostate and comorbidity. Eur Urol 2007;52:1028-
cancer on active surveillance. J Urol 1035.
2010;184:1942-1946.
141. Handley R, Carr TW, Travis D, et al.
131. Cooperberg MR, Cowan JE, Hilton JF, et al. Deferred treatment for prostate cancer. Br J
Outcomes of active surveillance for men Urol. 1988;62:249-253.
with intermediate-risk prostate cancer. J Clin
Oncol 2011;29:228-234. 142. Rana A, Chisholm GD, Christodoulou S, et
al. Audit and its impact in the management
132. Whitson JM, Porten SP, Hilton JF, et al. The of early prostatic cancer. Br J Urol
relationship between prostate specific 1993;71:721-727.
antigen change and biopsy progression in
patients on active surveillance for prostate 143. Chen WM, Yang CR, Ou YC, et al. Clinical
outcome of patients with stage T1a prostate
cancer. J Urol 2011;185:1656-1660.
cancer. J Chin Med Assoc 2003;66:236-240.
133. Chan JM, Weinberg V, Magbanua MJ, et al. 144. Holmberg L, Bill-Axelson A, Helgesen F, et
Nutritional supplements, COX-2 and IGF-1
expression in men on active surveillance for al. A randomized trial comparing radical
prostatectomy with watchful waiting in early
prostate cancer. Cancer Causes & Control
2011;22:141-150. prostate cancer. N Engl J Med
2002;347:781-789.
134. Giles SL, Morgan VA, Riches SF, et al.
Apparent diffusion coefficient as a 145. Bangma CH, HOP WCJ, Schroder FH.
Serial prostate specific antigen
predictive biomarker of prostate cancer
progression: value of fast and slow diffusion measurements and progression in untreated
confined (stages T0 to 3NxM0, grades 1 to
components. AJR 2011;American:586-591.
3) carcinoma of the prostate. J Urol.
1995;154:1403-1406.
99
